The buzz around Shattuck Labs is palpable! News of clinical trials and big investments are shaking things up. Despite RSI hovering around neutral, the chart reveals a potential cup-handle formation for beginners to spot. With the volume surge echoing excitement, I'd lean towards a BUY signal. Keep an eye on this one, the story seems to be just getting started. #ShattuckLabs #InvestingWisdom

Institutional headlines from BlackRock and Frazier bring noise, but the tape actually justifies the move. STTK spiked to 7.42 before fading to 6.82, leaving an upper wick that signals near-term supply. Still, heavy volume confirms authentic participation, and an RSI of 55 alongside price crossing above both moving averages shows healthy, unexhausted momentum. The hype is noisy, but the accumulation is real. Call it a buy.

News is doing heavy lifting: Phase 2 SL-325, institutional buying, and bullish initiations make STTK look like a momentum biotech story. Technically constructive: price above both WMAs, RSI mid 50s. But the huge volume spike faded from 7.42, leaving an upper wick that says money is taking profits. The TL1A pitch is no longer a secret, so chase risk is real. My call: BUY, but on dips near 6.50, not after a candle screams 'I like my money less.'

Big money's circling STTK like sharks at a chum line: BlackRock dropped $27M, insiders bought 3.75M shares, and that Phase 2 HS trial plus a fresh clinical hire scream pipeline momentum. The tape agrees: WMAs are stacking bullishly, RSI just crossed into healthy 55 territory, and that 9:30 volume spike on 9/30 was a buyer's flag on the play. This isn't a sleepy biotech, it's a coiled spring. BUY. 🚀

Conference season is heating up STTK! 💊 With fresh funding and a new IBD drug trial, the news flow is bullish. The stock just bounced off support, RSI is neutral (no exhaustion here), and that strong finish today suggests institutions are listening. This looks primed for a run into December events. BUY the momentum. #BiotechBounce

**Analysis:** Shattuck Labs (STTK) is showing wild volatility! 📈 The stock surged from $0.71 to $1.49 on April 7, closing at $1.30 with massive volume (3.3M vs. previous ~100K). The 9-day EMA crossed above the 21-day, hinting at short-term bullish momentum. RSI hit 73 (overbought), suggesting a possible pullback. News is mixed—positive clinical updates but legal investigations loom. 🚨 If you’re in, watch for a dip below $1.20 as a potential exit. High-risk, high-reward play!